SCHEMBL5044556

SCHEMBL5044556

C=CCNC(=O)c1cc(-c2csc(C(=O)OCC)n2)n(Cc2ccc(OC)cc2)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 5/20 0.43
PKM P14618 1/20 0.39
ALDH1A1 P00352 4/20 0.38
HPGD P15428 3/20 0.38
KLK1 P06870 2/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
TP53 P04637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 2/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
GLA P06280 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
FEN1 P39748 1/20 0.38
GSK3B P49841 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068954 0.89 ALDH1A1 (0.47) KLKB1ALDH1A1HPGDKLK1MAPT
SCHEMBL5043761 0.89 KLKB1 (0.44) KLKB1ALDH1A1HPGDKLK1MAPT
SCHEMBL5048628 0.88 HPGD (0.46) KLKB1ALDH1A1HPGDKLK1MAPT
SCHEMBL5046847 0.87 ALDH1A1 (0.49) KLKB1ALDH1A1HPGDKLK1MAPT
SCHEMBL5043301 0.87 KLKB1 (0.53) KLKB1PKMALDH1A1HPGDKLK1
SCHEMBL5039546 0.85 KLKB1 (0.43) KLKB1PKMALDH1A1KLK1MAPT
SCHEMBL6068958 0.83 ALDH1A1 (0.41) KLKB1ALDH1A1HPGDKLK1MAPT
SCHEMBL5048540 0.83 ALDH1A1 (0.48) PKMALDH1A1HPGDLMNAHSD17B10
SCHEMBL5048709 0.83 HPGD (0.45) KLKB1PKMALDH1A1HPGDKLK1
SCHEMBL5046987 0.82 KLKB1 (0.48) KLKB1ALDH1A1HPGDKLK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885PKM 2463/4885ALDH1A1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.